Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators.
Products, services, technology
- M4 PAM - Schizophrenia and other psychosis - Started IND enabling studies in Q3 2024
- mGlu7 NAM - Mood disorders - Start IND enabling studies in H1 2025
- mGlu2 NAM - Cognition - Enter clinical candidate selection in H1 2025
- Undisclosed - CNS - Start lead optimization in H1 2025
- https://www.neurosterix.com/
- +41228841555
- info@neurosterix.com
- Tim Dyer